NZ774167A - Therapeutic nuclease compositions and methods - Google Patents
Therapeutic nuclease compositions and methodsInfo
- Publication number
- NZ774167A NZ774167A NZ774167A NZ77416712A NZ774167A NZ 774167 A NZ774167 A NZ 774167A NZ 774167 A NZ774167 A NZ 774167A NZ 77416712 A NZ77416712 A NZ 77416712A NZ 774167 A NZ774167 A NZ 774167A
- Authority
- NZ
- New Zealand
- Prior art keywords
- domain
- polypeptide
- interferon
- modified
- rnase
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed is a hybrid nuclease molecule comprising a first nuclease domain and a modified Fc domain, wherein the first nuclease domain is operatively coupled to the Fc domain and wherein the Fc domain is modified such that the molecule has reduced cytotoxicity relative to a hybrid nuclease molecule having an unmodified Fc domain.
Claims (34)
1. Use of a polypeptide comprising an RNase domain and a modified Fc domain in the manufacture of a medicament for reducing or inhibiting interferon (IFN) production in a subject, wherein the RNase domain is operatively coupled to the modified Fc domain, wherein the modified Fc domain includes a P238S mutation and a P331S mutation, and wherein the polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 96, 92, 62, or 78.
2. The use of claim 1, wherein the polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 96.
3. Use of a polypeptide comprising an RNase domain, a DNase domain, and a modified Fc domain in the manufacture of a medicament for reducing or inhibiting interferon (IFN) production in a subject, wherein the RNase domain and the DNase domain are operatively coupled to the modified Fc domain, wherein the modified Fc domain includes a P238S mutation and a P331S mutation, and wherein the polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 94 or 98.
4. The use of claim 3, wherein the polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 98.
5. The use of any one of claims 1-4, wherein the interferon is a type I interferon.
6. The use of any one of claims 1-4, wherein the interferon is interferon-α.
7. The use of any one of claims 1-6, wherein the Fc domain has decreased binding to Fcγ receptors on human cells.
8. The use of any one of claims 1-7, wherein the polypeptide has at least 1, 2, 3, 4, or 5-fold less cytotoxicity relative to a polypeptide having wild type Fc domain.
9. The use of any one of claims 1-8, wherein the polypeptide degrades: (a) circulating RNA, DNA, or RNA and DNA; and/or (b) RNA, DNA, or RNA and DNA in immune complexes.
10. The use of any one of claims 1-9, wherein the polypeptide has increased serum half-life relative to the RNase domain alone.
11. The use of any one of claims 1-9, wherein the activity of the RNase is not less than 9-fold less than the activity of a control RNase molecule.
12. The use of any one of claims 1-9, wherein the activity of the RNase is equal to the activity of a control RNase molecule.
13. The use of any one of claims 3-13, wherein the activity of the DNase is not less than 9- fold less than the activity of a control DNase molecule.
14. The use of any one of claims 3-13, wherein the activity of the DNase is equal to the activity of a control DNase molecule.
15. The use of any one of claims 3-13, wherein the polypeptide has increased serum half-life relative to the DNase domain alone.
16. The use of any one of claims 1-15, wherein the polypeptide is a dimeric polypeptide.
17. The use of claim 16, wherein the dimeric polypeptide is a homodimer.
18. The use of any one of claims 1-17, wherein the production of interferon is inhibited.
19. The use of any one of claims 1-17, wherein the production of interferon is reduced.
20. The use of any one of claims 1-19, wherein the medicament further comprises a pharmaceutically acceptable carrier.
21. The use of any one of claims 1-20, wherein the medicament is formulated for intravenous administration.
22. Use of a dimeric polypeptide comprising a first polypeptide sequence and a second polypeptide sequence in the manufacture of a medicament for reducing or inhibiting interferon (IFN) production in a subject, wherein the first polypeptide sequence comprises an RNase domain and a modified Fc domain, wherein the RNase domain is operatively coupled to the modified Fc domain, wherein the modified Fc domain includes a P238S mutation and a P331S mutation, and wherein the first polypeptide sequence comprises an amino acid sequence set forth in SEQ ID NO: 96, 92, 62, or 78.
23. The use of claim 22, wherein the dimeric polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 96.
24. Use of a dimeric polypeptide comprising a first polypeptide sequence and a second polypeptide sequence in the manufacture of a medicament for reducing or inhibiting interferon (IFN) production in a subject, wherein the first polypeptide sequence comprises an RNase domain, a DNase domain, and a modified Fc domain, wherein the RNase domain and the DNase domain are operatively coupled to the modified Fc domain, wherein the modified Fc domain includes a P238S mutation and a P331S mutation, and wherein the first polypeptide sequence comprises an amino acid sequence set forth in SEQ ID NO: 94 or 98.
25. The use of claim 24, wherein the dimeric polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 98.
26. The use of any one of claims 22-25, wherein the dimeric polypeptide is a homodimer.
27. The use of any one of claims 22-26, wherein the interferon is a type I interferon.
28. The use of any one of claims 22-26, wherein the interferon is interferon-α.
29. The use of any one of claims 22-28, wherein the production of interferon is inhibited.
30. The use of any one of claims 22-28, wherein the production of interferon is reduced.
31. The use of any one of claims 22-30, wherein the medicament further comprises a pharmaceutically acceptable carrier.
32. The use of any one of claims 22-31, wherein the medicament is formulated for intravenous administration.
33. A method for producing the dimer of any one of claims 22-32, comprising: providing a host cell comprising a nucleic acid sequence that encodes the dimeric polypeptide, and maintaining the host cell under conditions in which the dimer is expressed, and wherein the host cell is not within a human.
34. The method of claim 33, further comprising obtaining the dimer. University of Washington By the Attorneys for the Applicant SPRUSON & FERGUSON
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480961P | 2011-04-29 | 2011-04-29 | |
| US201261617241P | 2012-03-29 | 2012-03-29 | |
| NZ753414A NZ753414A (en) | 2011-04-29 | 2012-04-27 | Therapeutic nuclease compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ774167A true NZ774167A (en) | 2022-12-23 |
Family
ID=84527796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ774167A NZ774167A (en) | 2011-04-29 | 2012-04-27 | Therapeutic nuclease compositions and methods |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ774167A (en) |
-
2012
- 2012-04-27 NZ NZ774167A patent/NZ774167A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Choudhry et al. | Prospects of IL-2 in cancer immunotherapy | |
| Martins et al. | Vaccine adjuvant uses of poly-IC and derivatives | |
| EP4289951A3 (en) | Circular rna compositions and methods | |
| Xia et al. | Applications and advances of CRISPR-Cas9 in cancer immunotherapy | |
| Bouguen et al. | Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases | |
| JP2021528493A (en) | Cytokine-based bioactive agents and how to use them | |
| US10815303B2 (en) | Fusion protein for restoring the functions of failing immune cells and application thereof | |
| Matthes et al. | Revisiting IL-6 antagonism in multiple myeloma | |
| Waldron et al. | Myeloid derived suppressor cells: targets for therapy | |
| MX2022014070A (en) | Circular rna compositions and methods. | |
| Schmidt et al. | Design and structural requirements of the potent and safe TLR-9 agonistic immunomodulator MGN1703 | |
| JP2016505539A5 (en) | ||
| CN104231068A (en) | Human interleukin II mutant and application thereof | |
| ZA202202410B (en) | Rna particles comprising polysarcosine | |
| WO2022036159A3 (en) | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms | |
| CN102174479A (en) | Oncolytic virus for targeted treatment of human tumors and application thereof | |
| Gu et al. | mRNA vaccines in the prevention and treatment of diseases | |
| Xu et al. | Cellular immunotherapy for hematological malignancy: recent progress and future perspectives | |
| NZ610538A (en) | Fgfr1 extracellular domain combination therapies | |
| NZ774167A (en) | Therapeutic nuclease compositions and methods | |
| Kreuser et al. | Biochemical modulation of cytotoxic drugs by cytokines: molecular mechanisms in experimental oncology | |
| Ferreri et al. | Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma | |
| CN102824306B (en) | Folic acid modified chitosan coated plasmid nanoparticles and preparation method thereof | |
| US11053503B2 (en) | Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition | |
| JP2022549741A (en) | Application of peginterferon and proto-oncogene product targeted inhibitors in synergistic treatment of renal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 27 APR 2025 BY SPRUSON + FERGUSON PTY LTD Effective date: 20230602 |